Trial Details
ACTIVE_NOT_RECRUITINGBasic Information
| Clinical ID | c780 |
|---|---|
| Identifier | NCT06063967 |
| Trial Title | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NO |
|---|---|
| Conditions | Crohn's Disease |
| Interventions | DRUG: Risankizumab SC|DRUG: Placebo for risankizumab |
Participant Information
| Sponsor | AbbVie |
|---|---|
| City | Sun City |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE3 |
Time Information
| Start Date | 2023-11-15 |
|---|---|
| Primary Completion Date | 2027-03 |
| Completion Date | 2027-03 |